Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q1 2026 · 10-Q
Revenue$102.25M$102.25M+17.4% vs Q1 2025 Net Income-$63.32M-$63.32MN/M vs Q1 2025 EPS Diluted-$2.16-$2.16N/M vs Q1 2025 Gross Profit$68,211,000+16.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flow-$32,408,000N/M Free Cash Flowderived-$38,861,000N/M Margins · derivedGross margin66.7%−0.4 pt vs Q1 2025
Operating margin-56.2%−51.0 pt vs Q1 2025
Net margin-61.9%−54.4 pt vs Q1 2025
ended Mar 31, 2026 · filed May 4, 2026 · 34 d after period end